Serum inhibin B during controlled ovarian hyperstimulation: an additional criterion for deciding whether to proceed with egg retrieval

Fertility and Sterility

Volumn 91, Issue 6, 2009, Pages 2419-2425

  Decanter, Christine ^a,b   Pigny, Pascal ^a   Lefebvre, Catherine ^a,b   Thomas, Patricia ^a,b   Leroy, Maryse ^a,b   Dewailly, Didier ^a,b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

Author keywords

dynamic inhibin B; IVF outcome; Oocytes; ovarian response; poor responders

Indexed keywords

INHIBIN B; PROGESTERONE; RECOMBINANT FOLLITROPIN; TRIPTORELIN;

ADULT; ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; FERTILIZATION IN VITRO; HORMONE DETERMINATION; HUMAN; INFERTILITY THERAPY; MAJOR CLINICAL STUDY; OOCYTE RETRIEVAL; OVARY HYPERSTIMULATION; PREDICTION; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; ROC CURVE; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

EID: 67349137043     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2008.03.037     Document Type: Article

References (42)

1. Kligman I., and Rosenwaks Z. Differentiating clinical profiles: predicting good responders, poor responders, and hyperresponders. Fertil Steril 76 (2001) 1185-1190
2. Bancsi L.F., Broekmans F.J., Mol B.W., Habbema J.D., and te Velde E.R. Performance of basal follicle-stimulating hormone in the prediction of poor ovarian response and failure to become pregnant after in vitro fertilization: a meta-analysis. Fertil Steril 79 (2003) 1091-1097
3. Groome N.P., Illingworth P.J., O'Brien M., Pai R., Rodger F.E., Mather J.P., et al. Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 81 (1996) 1401-1405
4. Welt C.K., and Schneyer A.L. Differential regulation of inhibin B and inhibin a by follicle-stimulating hormone and local growth factors in human granulosa cells from small antral follicles. J Clin Endocrinol Metab 86 (2001) 330-336
5. Josso N., di Clemente N., and Gouedard L. Anti-Müllerian hormone and its receptors. Mol Cell Endocrinol 179 (2001) 25-32
6. Weenen C., Laven J.S., Von Bergh A.R., Cranfield M., Groome N.P., Visser J.A., et al. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 10 (2004) 77-83
7. Seifer D.B., Lambert-Messerlian G., Hogan J.W., Gardiner A.C., Blazar A.S., and Berk C.A. Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertil Steril 67 (1997) 110-114
8. Danforth D.R., Arbogast L.K., Mroueh J., Kim M.H., Kennard E.A., Seifer D.B., et al. Dimeric inhibin: a direct marker of ovarian aging. Fertil Steril 70 (1998) 119-123
9. van Rooij I.A., Broekmans F.J., te Velde E.R., Fauser B.C., Bancsi L.F., de Jong F.H., et al. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 17 (2002) 3065-3071
10. Seifer D.B., MacLaughlin D.T., Christian B.P., Feng B., and Shelden R.M. Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 77 (2002) 468-471
11. Fanchin R., Schonauer L.M., Righini C., Guibourdenche J., Frydman R., and Taieb J. Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 18 (2003) 323-327
12. Visser J.A., de Jong F.H., Laven J.S., and Themmen A.P. Anti-Müllerian hormone: a new marker for ovarian function. Reproduction 131 (2006) 1-9
13. Feyereisen E., Mendez Lozano D.H., Taieb J., Hesters L., Frydman R., and Fanchin R. Anti-Müllerian hormone: clinical insights into a promising biomarker of ovarian follicular status. Reprod Biomed Online 12 (2006) 695-703
14. Hall J.E., Welt C.K., and Cramer D.W. Inhibin A and inhibin B reflect ovarian function in assisted reproduction but are less useful at predicting outcome. Hum Reprod 14 (1999) 409-415
15. Tinkanen H., Blauer M., Laippala P., Tuohimaa P., and Kujansuu E. Prognostic factors in controlled ovarian hyperstimulation. Fertil Steril 72 (1999) 932-936
16. Creus M., Penarrubia J., Fabregues F., Vidal E., Carmona F., Casamitjana R., et al. Day 3 serum inhibin B and FSH and age as predictors of assisted reproduction treatment outcome. Hum Reprod 15 (2000) 2341-2346
17. Bancsi L.F., Broekmans F.J., Eijkemans M.J., de Jong F.H., Habbema J.D., and te Velde E.R. Predictors of poor ovarian response in vitro fertilization: a prospective study comparing basal markers of ovarian reserve. Fertil Steril 77 (2002) 328-336
18. Seifer D.B., and Maclaughlin D.T. Müllerian inhibiting substance is an ovarian growth factor of emerging clinical significance. Fertil Steril 88 (2007) 539-546
19. Hazout A., Bouchard P., Seifer D.B., Aussage P., Junca A.M., and Cohen-Bacrie P. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril 82 (2004) 1323-1329
20. Muttukrishna S., McGarrigle H., Wakim R., Khadum I., Ranieri D.M., and Serhal P. Antral follicle count, anti-müllerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology?. BJOG 112 (2005) 1384-1390
21. Smeenk J.M., Sweep F.C., Zielhuis G.A., Kremer J.A., Thomas C.M., and Braat D.D. Antimüllerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracytoplasmic sperm injection. Fertil Steril 87 (2007) 223-226
22. La Marca A., Giulini S., Tirelli A., Bertucci E., Marsella T., Xella S., et al. Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 22 (2007) 766-771
23. Nelson S.M., Yates R.W., and Fleming R. Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles-implications for individualization of therapy. Hum Reprod 22 (2007) 2414-2421
24. Penarrubia J., Fabregues F., Manau D., Creus M., Casals G., Casamitjana R., et al. Basal and stimulation day 5 anti-Müllerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist-gonadotropin treatment. Hum Reprod 20 (2005) 915-922
25. Hehenkamp W.J.K., Looman C.W.N., Themmen A.P.N., de Jong F.H., te velde E.R., and Broekmans F.J.M. Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab 91 (2006) 4057-4063
26. Fanchin R., de Ziegler D., Olivennes F., Taieb J., Dzik A., and Frydman R. Exogenous follicle stimulating hormone ovarian reserve test (EFORT): a simple and reliable screening test for detecting 'poor responders' in in-vitro fertilization. Hum Reprod 9 (1994) 1607-1611
27. Wachs D.S., Coffler M.S., Malcom P.J., and Chang R.J. Serum anti-müllerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women. J Clin Endocrinol Metab 92 (2007) 1871-1874
28. Fanchin R., Schonauer L.M., Righini C., Frydman N., Frydman R., and Taieb J. Serum anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation. Hum Reprod 18 (2003) 328-332
29. Kwee J., Elting M.W., Schats R., Bezemer P.D., Lambalk C.B., and Schoemaker J. Comparison of endocrine tests with respect to their predictive value on the outcome of ovarian hyperstimulation in IVF treatment: results of a prospective randomized study. Hum Reprod 18 (2003) 1422-1427
30. Dzik A., Lambert-Messerlian G., Izzo V.M., Soares J.B., Pinotti J.A., and Seifer D.B. Inhibin B response to EFORT is associated with the outcome of oocyte retrieval in the subsequent in vitro fertilization cycle. Fertil Steril 74 (2000) 1114-1117
31. Elting M.W., Kwee J., Schats R., Rekers-Mombarg L.T., and Schoemaker J. The rise of estradiol and inhibin B after acute stimulation with follicle-stimulating hormone predict the follicle cohort size in women with polycystic ovary syndrome, regularly menstruating women with polycystic ovaries, and regularly menstruating women with normal ovaries. J Clin Endocrinol Metab 86 (2001) 1589-1595
32. Yong P.Y., Baird D.T., Thong K.J., McNeilly A.S., and Anderson R.A. Prospective analysis of the relationships between the ovarian follicle cohort and basal FSH concentration, the inhibin response to exogenous FSH and ovarian follicle number at different stages of the normal menstrual cycle and after pituitary down-regulation. Hum Reprod 18 (2003) 35-44
33. Eldar-Geva T., Ben-Chetrit A., Spitz I.M., Rabinowitz R., Markowitz E., Mimoni T., et al. Dynamic assays of inhibin B, anti-Müllerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Hum Reprod 20 (2005) 3178-3183
34. Broekmans F.J., Kwee J., Hendriks D.J., Mol B.W., and Lambalk C.B. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 12 (2006) 685-718
35. Scheffer G.J., Broekmans F.J., Dorland M., Habbema J.D., Looman C.W., and te Velde E.R. Antral follicle counts by transvaginal ultrasonography are related to age in women with proven natural fertility. Fertil Steril 72 (1999) 845-851
36. Porchet H.C., le Cotonnec J.Y., and Loumaye E. Clinical pharmacology of recombinant human follicle-stimulating hormone. III. Pharmacokinetic-pharmacodynamic modeling after repeated subcutaneous administration. Fertil Steril 61 (1994) 687-695
37. Penarrubia J., Balasch J., Fabregues F., Carmona F., Casamitjana R., Moreno V., et al. Day 5 inhibin B serum concentrations as predictors of assisted reproductive technology outcome in cycles stimulated with gonadotrophin-releasing hormone agonist-gonadotrophin treatment. Hum Reprod 15 (2000) 1499-1504
38. Eldar-Geva T., Robertson D.M., Cahir N., Groome N., Gabbe M.P., Maclachlan V., et al. Relationship between serum inhibin A and B and ovarian follicle development after a daily fixed dose administration of recombinant follicle-stimulating hormone. J Clin Endocrinol Metab 85 (2000) 607-613
39. Eldar-Geva T., Margalioth E.J., Ben-Chetrit A., Gal M., Robertson D.M., Healy D.L., et al. Serum inhibin B levels measured early during FSH administration for IVF may be of value in predicting the number of oocytes to be retrieved in normal and low responders. Hum Reprod 17 (2002) 2331-2337
40. Fawzy M., Lambert A., Harrison R.F., Knight P.G., Groome N., Hennelly B., et al. Day 5 inhibin B levels in a treatment cycle are predictive of IVF outcome. Hum Reprod 17 (2002) 1535-1543
41. Urbancsek J., Hauzman E., Klinga K., Rabe T., Papp Z., and Strowitzki T. Use of serum inhibin B levels at the start of ovarian stimulation and at oocyte pickup in the prediction of assisted reproduction treatment outcome. Fertil Steril 83 (2005) 341-348
42. le Contonnec J.Y., Porchet H.C., Beltrami V., Khan A., Toon S., and Rowland M. Clinical pharmacology of recombinant human follicle-stimulating hormone. II. Single doses and steady state pharmacokinetics. Fertil Steril 61 (1994) 679-686